Cxcl8 as a potential therapeutic target for hiv-associated neurocognitive disorders

Manmeet K. Mamik, Anuja Ghorpade

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chemokine CXCL8 is a low molecular weight neutrophil chemoattractant implicated in various neurodegenerative disorders including Alzheimers disease and stroke. Increased expression of CXCL8 has been reported in serum, plasma and brain of human immunodeficiency virus (HIV)-1 infected individuals with neurocognitive impairment, indicating its role in neuroinflammation associated with HIV-1 infection of the brain. Since chemokines are critical in eliciting immune responses in the central nervous system (CNS), CXCL8 is of particular importance for being one of the first chemokines described in the brain. Activation of astrocytes and microglia by HIV-1 and virus associated proteins results in production of this chemokine in the brain microenvironment. Consequently, CXCL8 exerts its effect on target cells via Gprotein coupled receptors CXCR1 and CXCR2. Neutrophils are the main target cells for CXCL8; however, microglia and neurons also express CXCR1/CXCR2 and therefore are important targets for CXCL8-mediated crosstalk. The objective of this review is to focus on CXCL8 production, signaling and regulation in neuronal and glial cells in response to HIV-1 infection. We highlight the role of HIV-1 secreted proteins such as trans-activator of transcription, envelope glycoprotein, negative regulatory factor and viral protein r in the regulation of CXCL8. We discuss dual role of CXCL8 in neurodegeneration as well as neuroprotection in the CNS. Thus, targeting CXCL8 through the development of CXCR1/CXCR2-based therapeutic strategies to either selectively agonize or antagonize receptors may be able to selectively promote neuroprotective and anti-inflammatory outcomes, leading to significant clinical applications in many neuroinflammatory CNS diseases, including HIV-associated neurocognitive disorders.

Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalCurrent Drug Targets
Volume17
Issue number1
StatePublished - 1 Jan 2016

Fingerprint

Viruses
HIV-1
Chemokines
Brain
Neurology
Microglia
Virus Diseases
Interleukin-8A Receptors
Viral Regulatory and Accessory Proteins
Neutrophils
Interleukin-8B Receptors
Central Nervous System
Therapeutics
Trans-Activators
Central Nervous System Diseases
Chemotactic Factors
Interleukin-8
Neuroglia
Astrocytes
Neurodegenerative Diseases

Keywords

  • CXCL8
  • CXCR1/CXCR2
  • Chemokines
  • HIV-1
  • Neurodegeneration
  • Neuroprotection

Cite this

Mamik, Manmeet K. ; Ghorpade, Anuja. / Cxcl8 as a potential therapeutic target for hiv-associated neurocognitive disorders. In: Current Drug Targets. 2016 ; Vol. 17, No. 1. pp. 111-121.
@article{044eb3bd06ba4d9f86f39ab18c4fb646,
title = "Cxcl8 as a potential therapeutic target for hiv-associated neurocognitive disorders",
abstract = "Chemokine CXCL8 is a low molecular weight neutrophil chemoattractant implicated in various neurodegenerative disorders including Alzheimers disease and stroke. Increased expression of CXCL8 has been reported in serum, plasma and brain of human immunodeficiency virus (HIV)-1 infected individuals with neurocognitive impairment, indicating its role in neuroinflammation associated with HIV-1 infection of the brain. Since chemokines are critical in eliciting immune responses in the central nervous system (CNS), CXCL8 is of particular importance for being one of the first chemokines described in the brain. Activation of astrocytes and microglia by HIV-1 and virus associated proteins results in production of this chemokine in the brain microenvironment. Consequently, CXCL8 exerts its effect on target cells via Gprotein coupled receptors CXCR1 and CXCR2. Neutrophils are the main target cells for CXCL8; however, microglia and neurons also express CXCR1/CXCR2 and therefore are important targets for CXCL8-mediated crosstalk. The objective of this review is to focus on CXCL8 production, signaling and regulation in neuronal and glial cells in response to HIV-1 infection. We highlight the role of HIV-1 secreted proteins such as trans-activator of transcription, envelope glycoprotein, negative regulatory factor and viral protein r in the regulation of CXCL8. We discuss dual role of CXCL8 in neurodegeneration as well as neuroprotection in the CNS. Thus, targeting CXCL8 through the development of CXCR1/CXCR2-based therapeutic strategies to either selectively agonize or antagonize receptors may be able to selectively promote neuroprotective and anti-inflammatory outcomes, leading to significant clinical applications in many neuroinflammatory CNS diseases, including HIV-associated neurocognitive disorders.",
keywords = "CXCL8, CXCR1/CXCR2, Chemokines, HIV-1, Neurodegeneration, Neuroprotection",
author = "Mamik, {Manmeet K.} and Anuja Ghorpade",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "111--121",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Cxcl8 as a potential therapeutic target for hiv-associated neurocognitive disorders. / Mamik, Manmeet K.; Ghorpade, Anuja.

In: Current Drug Targets, Vol. 17, No. 1, 01.01.2016, p. 111-121.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cxcl8 as a potential therapeutic target for hiv-associated neurocognitive disorders

AU - Mamik, Manmeet K.

AU - Ghorpade, Anuja

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Chemokine CXCL8 is a low molecular weight neutrophil chemoattractant implicated in various neurodegenerative disorders including Alzheimers disease and stroke. Increased expression of CXCL8 has been reported in serum, plasma and brain of human immunodeficiency virus (HIV)-1 infected individuals with neurocognitive impairment, indicating its role in neuroinflammation associated with HIV-1 infection of the brain. Since chemokines are critical in eliciting immune responses in the central nervous system (CNS), CXCL8 is of particular importance for being one of the first chemokines described in the brain. Activation of astrocytes and microglia by HIV-1 and virus associated proteins results in production of this chemokine in the brain microenvironment. Consequently, CXCL8 exerts its effect on target cells via Gprotein coupled receptors CXCR1 and CXCR2. Neutrophils are the main target cells for CXCL8; however, microglia and neurons also express CXCR1/CXCR2 and therefore are important targets for CXCL8-mediated crosstalk. The objective of this review is to focus on CXCL8 production, signaling and regulation in neuronal and glial cells in response to HIV-1 infection. We highlight the role of HIV-1 secreted proteins such as trans-activator of transcription, envelope glycoprotein, negative regulatory factor and viral protein r in the regulation of CXCL8. We discuss dual role of CXCL8 in neurodegeneration as well as neuroprotection in the CNS. Thus, targeting CXCL8 through the development of CXCR1/CXCR2-based therapeutic strategies to either selectively agonize or antagonize receptors may be able to selectively promote neuroprotective and anti-inflammatory outcomes, leading to significant clinical applications in many neuroinflammatory CNS diseases, including HIV-associated neurocognitive disorders.

AB - Chemokine CXCL8 is a low molecular weight neutrophil chemoattractant implicated in various neurodegenerative disorders including Alzheimers disease and stroke. Increased expression of CXCL8 has been reported in serum, plasma and brain of human immunodeficiency virus (HIV)-1 infected individuals with neurocognitive impairment, indicating its role in neuroinflammation associated with HIV-1 infection of the brain. Since chemokines are critical in eliciting immune responses in the central nervous system (CNS), CXCL8 is of particular importance for being one of the first chemokines described in the brain. Activation of astrocytes and microglia by HIV-1 and virus associated proteins results in production of this chemokine in the brain microenvironment. Consequently, CXCL8 exerts its effect on target cells via Gprotein coupled receptors CXCR1 and CXCR2. Neutrophils are the main target cells for CXCL8; however, microglia and neurons also express CXCR1/CXCR2 and therefore are important targets for CXCL8-mediated crosstalk. The objective of this review is to focus on CXCL8 production, signaling and regulation in neuronal and glial cells in response to HIV-1 infection. We highlight the role of HIV-1 secreted proteins such as trans-activator of transcription, envelope glycoprotein, negative regulatory factor and viral protein r in the regulation of CXCL8. We discuss dual role of CXCL8 in neurodegeneration as well as neuroprotection in the CNS. Thus, targeting CXCL8 through the development of CXCR1/CXCR2-based therapeutic strategies to either selectively agonize or antagonize receptors may be able to selectively promote neuroprotective and anti-inflammatory outcomes, leading to significant clinical applications in many neuroinflammatory CNS diseases, including HIV-associated neurocognitive disorders.

KW - CXCL8

KW - CXCR1/CXCR2

KW - Chemokines

KW - HIV-1

KW - Neurodegeneration

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84952056621&partnerID=8YFLogxK

M3 - Article

C2 - 26112047

AN - SCOPUS:84952056621

VL - 17

SP - 111

EP - 121

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 1

ER -